AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15042546 — intervention group
Group type: COMPARATOR
Intervention: High AGE diet (H-AGE)
Number of subjects: 189
Study 15042546 — intervention group
Group type: COMPARATOR
Intervention: Comparison of L-AGE and H-AGE groups
Number of subjects: 189
Study 11941338 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraction orthodontic treatment
Number of subjects: 24
Study 11941338 — intervention group
Group type: COMPARATOR
Intervention: Nonextraction orthodontic treatment
Number of subjects: 24
Study 9736563 — intervention group
Group type: EXPERIMENTAL
Intervention: Rufloxacin 200 mg once daily for days 2 to 7
Number of subjects: 12
Study 9736563 — intervention group
Group type: COMPARATOR
Intervention: Theophylline without rufloxacin
Number of subjects: 12
Study 7817333 — intervention group
Group type: EXPERIMENTAL
Intervention: Analgesic treatment consisting of water and sucrose
Number of subjects: 0
Study 7817333 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 0
Study 31329516 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide plus androgen deprivation therapy (ADT)
Number of subjects: 1150
Study 31329516 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide plus ADT
Number of subjects: 1150
Study 31329516 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus ADT
Number of subjects: 1150
Study 29798096 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Semont maneuver
Number of subjects: 130
Study 29798096 — intervention group
Group type: COMPARATOR
Intervention: Epley maneuver
Number of subjects: 130
Study 25903286 — intervention group
Group type: EXPERIMENTAL
Intervention: MVMH supplement
Number of subjects: 76
Study 25903286 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 24108248 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine or bupivacaine (5 mL or less)
Number of subjects: 142
Study 24108248 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine or bupivacaine (10 mL or greater)
Number of subjects: 142
Study 24108248 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection volumes of 2.5 and 5 mL
Number of subjects: 142
Study 24108248 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection volumes greater than or equal to 10 mL
Number of subjects: 142
Study 24108248 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mL of 0.5% bupivacaine or ropivacaine
Number of subjects: 142
Study 21420062 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced external counterpulsation (EECP)
Number of subjects: 42
Study 21420062 — intervention group
Group type: COMPARATOR
Intervention: Sham EECP
Number of subjects: 42
Study 19862391 — intervention group
Group type: EXPERIMENTAL
Intervention: PVS extra low viscosity (Panasil Contact Plus)
Number of subjects: 4
Study 19862391 — intervention group
Group type: EXPERIMENTAL
Intervention: PVS medium viscosity (Virtual Monophase)
Number of subjects: 4
Study 19862391 — intervention group
Group type: EXPERIMENTAL
Intervention: PVS low viscosity (Affinis Light Body)
Number of subjects: 4
Study 19862391 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyether low viscosity (Permadyne Garant)
Number of subjects: 4
Study 19862391 — intervention group
Group type: COMPARATOR
Intervention: All materials
Number of subjects: 4
Study 16440191 — intervention group
Group type: EXPERIMENTAL
Intervention: Unidimensional RECIST method
Number of subjects: 80
Study 16440191 — intervention group
Group type: COMPARATOR
Intervention: Bidimensional WHO method
Number of subjects: 80
Study 15045806 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led education programme
Number of subjects: 49
Study 15045806 — intervention group
Group type: EXPERIMENTAL
Intervention: Full ankle movement (> 60 degrees) and full mobility (without aid)
Number of subjects: 49
Study 11231996 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIGF‐I (20 microgram/kg, sc, at 0 min)
Number of subjects: 6
Study 11231996 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH (1 microgram/kg, iv, at 180 min)
Number of subjects: 6
Study 11231996 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin levels calculated over 270 min
Number of subjects: 6
Study 11231996 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose levels calculated over 270 min
Number of subjects: 6
Study 9562229 — intervention group
Group type: EXPERIMENTAL
Intervention: Test preparation (desmopressin nasal spray)
Number of subjects: 16
Study 9562229 — intervention group
Group type: COMPARATOR
Intervention: Reference preparation (desmopressin nasal spray)
Number of subjects: 16
Study 7876034 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioning stimulus and testing stimulus (identical auditory clicks) at 500 msec interval
Number of subjects: 20
Study 7876034 — intervention group
Group type: EXPERIMENTAL
Intervention: Count/no-count task introduction
Number of subjects: 20
Study 7876034 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-independent suppressing effect of a conditioning stimulus presentation
Number of subjects: 20
Study 7876034 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-dependent effect at the P50 range
Number of subjects: 20
Study 7876034 — intervention group
Group type: EXPERIMENTAL
Intervention: Full epoch data inspection
Number of subjects: 20
Study 2745258 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotetan 2 g
Number of subjects: 6
Study 2745258 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin 2 g
Number of subjects: 6
Study 2745258 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotetan
Number of subjects: 6
Study 2745258 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin
Number of subjects: 6
Study 961473 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid infusion during fructose infusion
Number of subjects: 0
Study 961473 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous administration of fructose and amino acids
Number of subjects: 0
Study 961473 — intervention group
Group type: COMPARATOR
Intervention: Fructose infusion without amino acids
Number of subjects: 0
Study 31542440 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS) procedure
Number of subjects: 187
Study 31727284 — intervention group
Group type: EXPERIMENTAL
Intervention: CMR-first strategy
Number of subjects: 207
Study 31727284 — intervention group
Group type: EXPERIMENTAL
Intervention: CTA-first strategy
Number of subjects: 207
Study 31727284 — intervention group
Group type: COMPARATOR
Intervention: Routine clinical care
Number of subjects: 207
Study 28806355 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated poliovirus vaccine
Number of subjects: 1301
Study 25100053 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported adherence to FTC/TDF
Number of subjects: 150
Study 25100053 — intervention group
Group type: EXPERIMENTAL
Intervention: Pill-count data
Number of subjects: 150
Study 25100053 — intervention group
Group type: EXPERIMENTAL
Intervention: Four adherence measures
Number of subjects: 150
Study 25100053 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of oral contraceptives
Number of subjects: 150
Study 25100053 — intervention group
Group type: EXPERIMENTAL
Intervention: Weeks of time in the study
Number of subjects: 150
Study 23441589 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible cystoscopy (group 1, n=40)
Number of subjects: 80
Study 23441589 — intervention group
Group type: COMPARATOR
Intervention: Rigid cystoscopy (group 2, n=40)
Number of subjects: 80
Study 22082698 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced intervention (educational brochure plus activities designed to enhance beliefs about stroke)
Number of subjects: 26
Study 22082698 — intervention group
Group type: COMPARATOR
Intervention: Standard intervention (educational brochure plus activities that were not about stroke)
Number of subjects: 26
Study 18486235 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine 37.5-375 mg daily
Number of subjects: 83
Study 18486235 — intervention group
Group type: COMPARATOR
Intervention: Lithium 300-2100 mg daily
Number of subjects: 83
Study 18486235 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 83
Study 18486235 — intervention group
Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 83
Study 17286342 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad-spectrum treatment (BST) with naltrexone
Number of subjects: 149
Study 17286342 — intervention group
Group type: COMPARATOR
Intervention: Motivational-enhancement therapy (MET) with naltrexone
Number of subjects: 149
Study 14712408 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol A (single injection of Gd‐BOPTA)
Number of subjects: 80
Study 14712408 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol B (two injections of Gd‐BOPTA)
Number of subjects: 80
Study 14712408 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Protocols (without pedal station)
Number of subjects: 80
Study 14712408 — intervention group
Group type: COMPARATOR
Intervention: Protocol A
Number of subjects: 80
Study 14712408 — intervention group
Group type: COMPARATOR
Intervention: Protocol B
Number of subjects: 80
Study 10749620 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) treatment (0.3 U/kg/day)
Number of subjects: 20
Study 10749620 — intervention group
Group type: COMPARATOR
Intervention: Control group (no GH treatment)
Number of subjects: 20
Study 8969390 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl/propofol/nitrous oxide/vecuronium anesthesia with early extubation (group 1A)
Number of subjects: 50
Study 8969390 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl/midazolam/vecuronium anesthesia with late extubation (group 1B)
Number of subjects: 50
Study 8969390 — intervention group
Group type: COMPARATOR
Intervention: Pneumonectomy (group 2)
Number of subjects: 50
Study 1425615 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 1 microgram kg‐1 i.v.
Number of subjects: 10
Study 1425615 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 6539381 — intervention group
Group type: EXPERIMENTAL
Intervention: Epsilon aminocaproic acid
Number of subjects: 61
Study 6539381 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 30977390 — intervention group
Group type: EXPERIMENTAL
Intervention: Draft addendum E9/R1
Number of subjects: 0
Study 30977390 — intervention group
Group type: EXPERIMENTAL
Intervention: Case study from the diabetes therapeutic area
Number of subjects: 0
Study 30716797 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratympanic dexamethasone (3 times, every 2 days)
Number of subjects: 90
Study 30716797 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratympanic dexamethasone (5 times, every 2 days)
Number of subjects: 90
Study 30716797 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall recovery (both groups combined)
Number of subjects: 90
Study 30716797 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval between onset of symptoms and therapy
Number of subjects: 90
Study 30716797 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence rate of vertigo
Number of subjects: 90
Study 26577199 — intervention group
Group type: EXPERIMENTAL
Intervention: Humidified high-flow nasal cannula (HFNC)
Number of subjects: 303
Study 26577199 — intervention group
Group type: COMPARATOR
Intervention: Standard O2
Number of subjects: 303
Study 24865871 — intervention group
Group type: EXPERIMENTAL
Intervention: Child Life and Attention Skills (CLAS) program
Number of subjects: 199
Study 24865871 — intervention group
Group type: COMPARATOR
Intervention: Parent-focused treatment (PFT)
Number of subjects: 199
Study 24865871 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 199
Study 21104601 — intervention group
Group type: EXPERIMENTAL
Intervention: Student tutors (ST)
Number of subjects: 46
Study 21104601 — intervention group
Group type: COMPARATOR
Intervention: Faculty staff sonographer (FS)
Number of subjects: 46
Study 21104601 — intervention group
Group type: COMPARATOR
Intervention: Comparison of improvement between ST and FS
Number of subjects: 46
Study 19531591 — intervention group
Group type: COMPARATOR
Intervention: LATER subgroup (MENA 14.0 ± 0.7 years)
Number of subjects: 124
Study 17688760 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Health Questionnaire (PHQ-9)
Number of subjects: 93
Study 17688760 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Outcomes in Routine Evaluation-Outcome Measure (CORE-OM)
Number of subjects: 93
Study 15172464 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous streptokinase (SK)
Number of subjects: 395
Study 15172464 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary intervention (PCI)
Number of subjects: 395
Study 15172464 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes (as a condition)
Number of subjects: 395
Study 12238408 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced home visitation (cognitive component)
Number of subjects: 96
Study 12238408 — intervention group
Group type: COMPARATOR
Intervention: Control condition (unenhanced home visitation)
Number of subjects: 96
Study 12238408 — intervention group
Group type: COMPARATOR
Intervention: Unenhanced home visitation
Number of subjects: 96
Study 12238408 — intervention group
Group type: EXPERIMENTAL
Intervention: Program features (cognitive component)
Number of subjects: 96
Study 9839777 — intervention group
Group type: EXPERIMENTAL
Intervention: Teril 600 CR tablet
Number of subjects: 3
Study 9839777 — intervention group
Group type: EXPERIMENTAL
Intervention: CBZ 600 granulate
Number of subjects: 3
Study 9839777 — intervention group
Group type: COMPARATOR
Intervention: Timonil 600 Retard tablet
Number of subjects: 3
Study 7862232 — intervention group
Group type: COMPARATOR
Intervention: Typical treatment
Number of subjects: 98
Study 7862232 — intervention group
Group type: EXPERIMENTAL
Intervention: Typical treatment + ganglioside GM1 (100 mg daily for 30 days, i.v. for first 5 days, then i.m.)
Number of subjects: 98
Study 7862232 — intervention group
Group type: EXPERIMENTAL
Intervention: Typical treatment + ganglioside GM1
Number of subjects: 98
Study 2678427 — intervention group
Group type: EXPERIMENTAL
Intervention: Ileal conduit
Number of subjects: 70
Study 2678427 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonic conduit
Number of subjects: 70
Study 2678427 — intervention group
Group type: EXPERIMENTAL
Intervention: Continent caecal reservoir
Number of subjects: 70
Study 2678427 — intervention group
Group type: EXPERIMENTAL
Intervention: Refluxing ureterointestinal anastomosis
Number of subjects: 70
Study 2678427 — intervention group
Group type: EXPERIMENTAL
Intervention: Antirefluxing ureterointestinal anastomosis
Number of subjects: 70
Study 1094960 — intervention group
Group type: EXPERIMENTAL
Intervention: Halcinonide cream
Number of subjects: 0
Study 1094960 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone valerate cream
Number of subjects: 0
Study 30267702 — intervention group
Group type: EXPERIMENTAL
Intervention: Fisher technique
Number of subjects: 50
Study 30267702 — intervention group
Group type: COMPARATOR
Intervention: Mohler technique
Number of subjects: 50
Study 28940312 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 μg LSD administered orally
Number of subjects: 20
Study 26255517 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at Yaotongdian (Extra) after massage
Number of subjects: 150
Study 26255517 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at Houxi (SI 3) after massage
Number of subjects: 150
Study 26255517 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at Weizhong (BL 40) after massage
Number of subjects: 150
Study 26255517 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at Chengshan (BL 57) after massage
Number of subjects: 150
Study 26255517 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at Shuigou (GV 26) after massage
Number of subjects: 150
Study 23817954 — intervention group
Group type: EXPERIMENTAL
Intervention: PICC method (group B)
Number of subjects: 80
Study 23817954 — intervention group
Group type: COMPARATOR
Intervention: CVC method (group A)
Number of subjects: 80
Study 21633025 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sitamaquine, 2 mg/kg/day, once a day for 21 days
Number of subjects: 61
Study 21633025 — intervention group
Group type: COMPARATOR
Intervention: Intravenous amphotericin B (AmB), 1 mg/kg every other day for 30 days
Number of subjects: 61
Study 19250074 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized VV delay programming (OPT)
Number of subjects: 48
Study 19250074 — intervention group
Group type: COMPARATOR
Intervention: Simultaneous biventricular stimulation (SIM)
Number of subjects: 48
Study 16923135 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg zinc sulfate three times daily
Number of subjects: 0
Study 16923135 — intervention group
Group type: COMPARATOR
Intervention: Identical placebo tablet three times daily
Number of subjects: 0
Study 16923135 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg zinc sulfate three times daily (after crossover)
Number of subjects: 0
Study 16923135 — intervention group
Group type: COMPARATOR
Intervention: Identical placebo tablet three times daily (after crossover)
Number of subjects: 0
Study 15252069 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent people renting their home
Number of subjects: 6298
Study 15252069 — intervention group
Group type: EXPERIMENTAL
Intervention: People living with someone other than spouse renting their home
Number of subjects: 6298
Study 10857970 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone (600 mg/day) for 12 weeks
Number of subjects: 27
Study 9120161 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory training program
Number of subjects: 9
Study 9120161 — intervention group
Group type: COMPARATOR
Intervention: Control group (physically inactive)
Number of subjects: 9
Study 1440306 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine 20 mg/day
Number of subjects: 0
Study 1440306 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine 40 mg/day
Number of subjects: 0
Study 1440306 — intervention group
Group type: COMPARATOR
Intervention: Nitrendipine (20 mg once or twice a day)
Number of subjects: 0
Study 1440306 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine 10 mg twice a day
Number of subjects: 0
Study 1440306 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine 20 mg once a day
Number of subjects: 0
Study 1440306 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine 20 mg twice a day
Number of subjects: 0
Study 3700308 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise anticipation
Number of subjects: 15
Study 3700308 — intervention group
Group type: COMPARATOR
Intervention: Mental arithmetic tasks
Number of subjects: 15
Study 29420221 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant transarterial chemoembolization (TACE)
Number of subjects: 280
Study 29420221 — intervention group
Group type: COMPARATOR
Intervention: Control (no adjuvant treatment)
Number of subjects: 280
Study 26762911 — intervention group
Group type: EXPERIMENTAL
Intervention: BFD (standard dose)
Number of subjects: 182
Study 26762911 — intervention group
Group type: EXPERIMENTAL
Intervention: BFD-LD (low dose)
Number of subjects: 182
Study 26762911 — intervention group
Group type: COMPARATOR
Intervention: PES (first-generation paclitaxel-eluting stents)
Number of subjects: 182
Study 26762911 — intervention group
Group type: COMPARATOR
Intervention: BFD, BFD-LD, PES (5-year outcomes)
Number of subjects: 182
Study 25579140 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactol probiotic
Number of subjects: 30
Study 25579140 — intervention group
Group type: COMPARATOR
Intervention: Control group (no lactol)
Number of subjects: 30
Study 22999589 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchoscopic argon plasma coagulation plus routine antituberculosis chemotherapy
Number of subjects: 115
Study 22999589 — intervention group
Group type: COMPARATOR
Intervention: Routine antituberculosis chemotherapy
Number of subjects: 115
Study 20801496 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg dabigatran
Number of subjects: 18113
Study 20801496 — intervention group
Group type: EXPERIMENTAL
Intervention: 110 mg dabigatran
Number of subjects: 18113
Study 20801496 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 18113
Study 18254486 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine nasal spray, 2 sprays per nostril twice daily
Number of subjects: 151
Study 18254486 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone nasal spray, 2 sprays per nostril once daily
Number of subjects: 151
Study 18254486 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of azelastine nasal spray and fluticasone nasal spray
Number of subjects: 151
Study 17006062 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine administration postoperatively
Number of subjects: 22
Study 14746666 — intervention group
Group type: EXPERIMENTAL
Intervention: Program to enhance health literacy
Number of subjects: 81
Study 14746666 — intervention group
Group type: COMPARATOR
Intervention: Standard care only
Number of subjects: 81
Study 10404919 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Care Clinics intervention (96 patients)
Number of subjects: 169
Study 10404919 — intervention group
Group type: COMPARATOR
Intervention: Usual care (73 patients)
Number of subjects: 169
Study 8867642 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% diclofenac/2.5% sodium hyaluronate topical gel, applied 4 times daily for 2 weeks
Number of subjects: 119
Study 8867642 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel lacking the active substance
Number of subjects: 119
Study 1903999 — intervention group
Group type: EXPERIMENTAL
Intervention: Trisdine bladder instillations
Number of subjects: 37
Study 1903999 — intervention group
Group type: COMPARATOR
Intervention: O'Neil catheter
Number of subjects: 37
Study 7362956 — intervention group
Group type: EXPERIMENTAL
Intervention: Short peroperative course of cefamandole
Number of subjects: 79
Study 7362956 — intervention group
Group type: COMPARATOR
Intervention: 3-day course of cephradine (Control)
Number of subjects: 79
Study 29584458 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilnidipine (10 mg/day) for 12 weeks
Number of subjects: 51
Study 29584458 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 51
Study 27649776 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol + Brivaracetam
Number of subjects: 18
Study 26095381 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered 4% articaine with 1:100,000 epinephrine
Number of subjects: 80